Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
Sponsor: Sanofi
A observational or N/A phase clinical study on Locally Advanced or Metastatic Medullary Thyroid Cancer and Medullary Thyroid Cancer, this trial is completed. The trial is conducted by Sanofi and has accumulated 18 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
18 versions recorded-
Apr 18, 2026 — Present [daily]
Completed
Phase: PHASE3 → None
-
Sep 2025 — Apr 2026 [monthly]
Completed PHASE3
-
May 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 13 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anderlecht, Belgium , Athens, Greece , Athens, Greece , Beijing, China , Beijing, China , Brussels, Belgium , Essen, Germany , Essen, Germany , Glasgow, United Kingdom , Glasgow, United Kingdom and 56 more locations